Vice President of Chemistry
Recursion
Joseph earned his BA in Chemistry from Southern Utah University in 2005, followed by graduate studies at the California Institute of Technology. After a year, he moved with his research advisor, David MacMillan, to Princeton University, where he completed his MA and Ph.D. in organic chemistry, focusing on asymmetric organocatalysis in complex natural product total synthesis. In 2010, Joseph joined Bristol-Myers Squibb as a medicinal chemist, contributing to early discovery efforts in obesity, metabolic diseases, and fibrosis. He led cross-functional teams and advanced projects from screening hits to lead optimization. Notably, he discovered the FXR agonist BMS-986318, which progressed to clinical trials for NASH. In 2019, Joseph joined Recursion Pharmaceuticals, where he led the C. difficile discovery project, resulting in Recursion’s first NCE clinical candidate, REC-3964, for recurrent C. difficile infections. He currently serves as Vice President of Medicinal Chemistry at Recursion, where he has been pivotal in building the Molecular Technologies team—encompassing medicinal, digital, and computational chemistry—and shaping the company’s industrialized approach to drug discovery.
Disclosure information not submitted.
The Future is Now: Understanding the Influence of AI and ML on Biotech Careers
Tuesday, October 22, 2024
1:30 PM – 2:30 PM MT